Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Urology
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Infectious Disease
•
Primary Care
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
Related Questions
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
Is there any role for administering another course of recombinant zoster vaccine (Shingrix) in a previously vaccinated patient with RA, who is in clinical remission on JAK inhibitor but has had a breakthrough shingles infection?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
What is your treatment approach for a young female who has an idiopathic small right elbow effusion with synovial thickening that has resulted in limitation in her range of motion?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
What is your approach to work up for patients referred for early onset osteoarthritis?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
